Dr. Venook Discusses the Results of the 80405 Trial

Alan P. Venook, MD
Published Online: Friday, August 15, 2014
Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses results from the CALGB/SWOG 80405 trial of targeted therapies administered in colorectal cancer.

Venook says this trial took 10 years to complete. This study originally set out to find the best first-line treatment for patients with metastatic colorectal cancer. However, the trial ended up focusing only on patients with wild-type KRAS at codons 12 and 13.

The trial enrolled 1137 patients that were randomized between bevacizumab and cetuximab with chemotherapy, Venook says. The results showed a survival of 29.9 months in the cetuximab arms and 29.0 months in the bevacizumab arms.

Online CME Activities
Free CME from PER
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
Pancreatic Cancer: Novel and Emerging Approaches to Early Detection and Treatment
Oncology Best Practice: Challenges in Treating Chronic Lymphocytic Leukemia – The Older Patient and Comorbid Conditions
OncoLogue: Breast Cancer Cases
More Reading
Publications
$auto_registration$